Freenome freenome.com


Public list: Digital Health (6428) Artificial Intelligence ( AI ) in Healthcare (399) Artificial Intelligence ( AI ) (3968) Genomics (614) Smart Money VCs (6327) 2017 Game Changers (36) AI 100 (100) Game Changers 2016 (36) The Digital Hospital (122) AI 100 2018 (100) Google In Healthcare (60) HLTH (200)

Freenome is a health technology company bringing accurate, accessible and non-invasive disease screenings to patients and their doctors to proactively treat cancer and other diseases at their most manageable stages.

Freenome is a health technology company bringing accurate, accessible and non-invasive disease screenings to patients and their doctors to proactively treat cancer and other diseases at their most manageable stages.

Company (Alive / Active)

Phone: 831-704-6883

Fax:

201 Gateway Boulevard

South San Francisco, 94080
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Freenome $79.1M Aug 14, 2017
See all 12 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Freenome Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 21 investors

Board Members

Competitors

Company Status Description Investors

Armune Bioscience

Kalamazoo, Michigan, United States
AcquiredArmune BioScience is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers.Login to see details

20/20 GeneSystems

Rockville, Maryland, United States
Alive / Active20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.Login to see details
See all 12 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)